Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Songling Xuemai Kang Capsules
- Development stage
- Phase 2
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Songling Xuemai Kang Capsules (SXC) is a traditional Chinese patent medicine developed by Chengdu Kanghong Pharmaceutical and its subsidiary Sichuan Jishengtang Pharmaceutical. Approved in China in 1996, it is formulated from three main natural ingredients: fresh pine needles, *Pueraria lobata* (Gegen), and pearl powder. It is primarily indicated for the treatment of primary hypertension and primary hyperlipidemia, particularly in patients presenting with symptoms of liver-yang hyperactivity such as headache, dizziness, irritability, palpitations, and insomnia. Mechanistically, the capsule exerts its therapeutic effects by regulating the renin-angiotensin-aldosterone system (RAAS), improving vascular endothelial function, reducing blood viscosity, and providing antioxidant and central sedative effects. In addition to its approved cardiovascular indications, Songling Xuemai Kang Capsules are being evaluated in Phase II clinical trials for functional premature ventricular contractions caused by non-organic heart disease and cerebral small vessel disease.
- Brand names
- Songling Xuemai Kang Capsules松龄血脉康胶囊
- Other names
- Songling Xuemaikang CapsuleSongling Xuemaikang Capsules
02
Targets
CAV1 (Caveolin-1)CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)CASP9 (Caspase-9)IGF-1R (Insulin-like growth factor 1 receptor)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Songling Xuemai Kang Capsules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Songling Xuemai Kang Capsules.